The short answer
Reported work describes Selank influencing GABAergic signalling through changes in GABA-A receptor expression in the hippocampus, rather than by binding the receptor itself. That is mechanistically distinct from benzodiazepines, which are direct positive allosteric modulators at the GABA-A receptor.
Key facts
- System
- GABAergic (inhibitory)
- Reported effect
- Altered GABA-A receptor expression
- Region cited
- Hippocampus
- Direct receptor binding
- Not described
- Benzodiazepine mechanism
- Direct allosteric modulation
- Model organism
- Rodent
How GABA-A signalling normally works
GABA is the principal inhibitory neurotransmitter in the mammalian brain. The GABA-A receptor is a ligand-gated chloride channel: when GABA binds, chloride enters and the neuron becomes less likely to fire. Its activity can be modulated by compounds binding at sites distinct from the GABA site itself. This is what positive allosteric modulation means.
What benzodiazepines do
Benzodiazepines bind a specific allosteric site on the GABA-A receptor and increase the receptor's response to GABA. They do not open the channel themselves; they amplify the effect of GABA when it is present. Because that amplification is immediate and dose-dependent, the pharmacology is fast, powerful and associated with tolerance on sustained exposure.
Research material referenced
Selank 10mg, third-party HPLC tested
What is reported for Selank
The published description is different in kind. Selank has been reported to influence inhibitory signalling in the hippocampus through changes in GABA-A receptor expression rather than by binding the receptor. An expression-level effect operates on a slower timescale than allosteric modulation (receptor protein has to be made), and it is a distinct pharmacological category, not a variation on the same theme.
Why the distinction needs care
It is tempting to translate 'different mechanism from benzodiazepines' into a claim about comparative safety or dependence. That is not a claim the mechanism supports on its own, and it is not one that can be made about material supplied for laboratory research. What can be said accurately is narrower: the reported mechanism is expression-level rather than direct allosteric modulation, and those are different pharmacological categories.
How it sits alongside the other reported activities
GABAergic effects, enkephalinase inhibition and BDNF expression are three separately reported activities. Whether they are causally connected, or which is primary, is not established by the published work. Treating them as one unified mechanism overstates what has been shown; the literature describes several observations rather than one confirmed pathway.
Frequently asked questions
Does Selank bind the GABA receptor?
Reported work describes effects on GABA-A receptor expression rather than direct binding to the receptor.
Is that the same as how benzodiazepines work?
No. Benzodiazepines are direct positive allosteric modulators at the GABA-A receptor. An expression-level effect is a different pharmacological category operating on a slower timescale.
Are Selank's reported mechanisms connected to each other?
Not established. Enkephalinase inhibition, GABAergic effects and BDNF expression are separately reported observations rather than one confirmed pathway.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedZozulia AA et al., Efficacy and possible mechanisms of the peptide anxiolytic selank. 2008 (PMID 18454096)pubmed.ncbi.nlm.nih.gov
- PubMedKolik LG et al., Selank, peptide analogue of tuftsin. Bull Exp Biol Med 2019 (PMID 31625062)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Selank (Tuftsin Analogue) articles
- Selank Storage, Stability and ReconstitutionSelank has no cysteine and no methionine, so the two usual degradation routes do not apply. What that changes about handling, and what it does not.
- Selank in the Published LiteratureAbout 135 indexed PubMed records, against 690 for its parent peptide tuftsin. How the mechanistic and clinical literatures split, and how to read them.
- What Is Selank? Sequence, Origin and Enkephalin MechanismSelank is a synthetic heptapeptide built from tuftsin with a Pro-Gly-Pro extension. Structure, enkephalin mechanism, regulatory status and the evidence base.
- Selank's Enkephalinase MechanismSelank does not bind opioid receptors. Reported work shows it inhibits enkephalin-degrading enzymes, extending the half-life of the body's own enkephalins.